Cargando…

Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus

Background: Hydroxychloroquine (HCQ) is an antimalarial agent given to patients with systemic lupus erythematosus (SLE) as first-line therapy. It alleviates childhood-onset systemic lupus erythematosus cSLE skin and musculoskeletal disease, decreasing disease activity and flares. HCQ concentration–e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zahr, Noël, Urien, Saik, Funck-Brentano, Christian, Vantomme, Hélène, Garcelon, Nicolas, Melki, Isabelle, Boistault, Margaux, Boyer, Olivia, Bader-Meunier, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002378/ https://www.ncbi.nlm.nih.gov/pubmed/33802811 http://dx.doi.org/10.3390/ph14030273

Ejemplares similares

Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19
por: Zahr, Noël, et al.
Publicado: (2021)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
por: Zahr, Noël, et al.
Publicado: (2022)

RETRACTED: Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

Hydroxychloroquine ototoxicity in a patient with systemic lupus erythematosus
por: Fernandes, Mariana Rita de Novaes, et al.
Publicado: (2018)

Hydroxychloroquine-induced retinal toxicity in systemic lupus erythematosus
por: Piggott, Kisha D, et al.
Publicado: (2018)

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
por: Dima, Alina, et al.
Publicado: (2022)

Successful treatment of massive ascites due to lupus peritonitis with hydroxychloroquine in old- onset lupus erythematosus
por: Hammami, Sonia, et al.
Publicado: (2014)

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies
por: Leclerc, Elisabeth, et al.
Publicado: (2018)

Multichannel perimetric alterations in systemic lupus erythematosus treated with hydroxychloroquine
por: Piñero, David P., et al.
Publicado: (2017)

Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine
por: Aouhab, Z., et al.
Publicado: (2019)

Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus
por: Fasano, Serena, et al.
Publicado: (2023)

Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment
por: Olsen, Nancy J., et al.
Publicado: (2016)

Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus
por: Floris, Alberto, et al.
Publicado: (2018)

Systemic Lupus Erythematosus: Perinatal Outcomes in Patients Treated With and Without Hydroxychloroquine
por: Baalbaki, Sima, et al.
Publicado: (2020)

Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
por: Urien, Saik, et al.
Publicado: (2013)

Pediatric systemic lupus erythematosus and human parvovirus B19 infection
por: Bélien-Pallet, V, et al.
Publicado: (2011)

Extensive Discoid Lupus Erythematosus in a HIV patient Responding to Hydroxychloroquine Monotherapy
por: Bhagwat, Pradeep Vittal, et al.
Publicado: (2012)

Incidental retinal vascular occlusions on hydroxychloroquine screening in patients with systemic lupus erythematosus
por: Bajwa, Asima, et al.
Publicado: (2015)

Hydroxychloroquine-Induced Psoriasis-form Erythroderma in a Patient with Systemic Lupus Erythematosus
por: Wang, Wen-Ming, et al.
Publicado: (2018)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus
por: Abdelbaky, Mohammed Salah Eldin, et al.
Publicado: (2021)

Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine
por: Reynolds, John A, et al.
Publicado: (2022)

Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine
por: O'Laughlin, John P., et al.
Publicado: (2016)

Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study
por: Fernandez-Ruiz, Ruth, et al.
Publicado: (2020)

Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus
por: Leung, Alexander KC, et al.
Publicado: (2020)

Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose
por: Wakiya, Risa, et al.
Publicado: (2020)

Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
por: Cornwell, MacIntosh Grant, et al.
Publicado: (2021)

Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report
por: Wang, Gang, et al.
Publicado: (2021)

Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus
por: Lee, Jae-Eun, et al.
Publicado: (2023)

Juvenile Neuropsychiatric Systemic Lupus Erythematosus: Identification of Novel Central Neuroinflammation Biomarkers
por: Labouret, Mathilde, et al.
Publicado: (2022)

14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE)
por: Bader-Meunier, B, et al.
Publicado: (2008)

SHARE – workpackage 5 : evidence based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus
por: Groot, Noortje, et al.
Publicado: (2014)

PReS-FINAL-2353: Are rasopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus?
por: Bader-Meunier, B, et al.
Publicado: (2013)

Response to the editorial “COVID-19 in patients with cardiovascular diseases”: Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection
por: Rodero, Mathieu Paul, et al.
Publicado: (2021)

Correction to: Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection
por: Rodero, Mathieu Paul, et al.
Publicado: (2021)

Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients
por: da Silva, Juliana Cruz, et al.
Publicado: (2013)

Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus
por: Yang, Deng-Ho, et al.
Publicado: (2019)

Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease
por: Salgado Guerrero, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_93kh27l8e4ashuioe2ean9rct3